CXCL12 and cancer: In a model of pancreatic ductal adenocarcinoma (PDAC), inhibiting the CXCL-12/CXCR4 axis mediated by cancer-associated fibroblasts (CAFs) using the CXCR4 inhibitor AMD3100 resulted in enhanced accumulation of T cells and regression of cancer [237].